FDA warns NSE Products (Nu Skin) over incomplete drug listing data for AP-24 products and 61 inactivated listings.
What happened
FDA reviewed the firm’s electronic Drug Registration and Listing System (eDRLS) information, the FDA database for drug listings. FDA sent a December 10, 2025 deficiency letter, followed up, and on January 24, 2026 issued a data removal notice. It found AP-24 listings naming a manufacturing establishment that confirmed it had not made these drugs for more than five years with no end marketing date, and 61 drug listings that had not been updated or certified and were inactivated.
What FDA found
The firm did not provide complete, accurate, up-to-date drug listing information as required.
section 510(j) of the FD&C Act, 21 U.S.C. 360(j)The listings cited a manufacturing establishment that had not made the drugs for more than five years and had no end marketing date.
21 CFR 207.57(b)(1)(iv); 21 CFR 207.49(a)(12)The firm did not review and update its drug listing information each June and December.
section 510(j)(2) of the FD&C Act, 21 U.S.C. 360(j)(2); 21 CFR 207.57(b)Sixty-one drug listings were not updated or certified as required and were inactivated by FDA.
21 CFR 207.57(b)Failure to provide drug listing information as required is prohibited.
section 301(p) of the FD&C Act, 21 U.S.C. 331(p)
What FDA wants
FDA asks the company to update the listing information to current status or add end marketing dates for discontinued drugs, and to respond in writing within 15 working days with corrective steps and documentation.
Who should pay attention
- drug companies that submit eDRLS listing data
- contract manufacturers named in drug listings
- sellers and distributors of listed drug products
This is a summary. Read the original letter on fda.gov.